Mutation of regulatory phosphorylation sites in PFKFB2 does not affect the anti-fibrotic effect of metformin in the kidney
The anti-fibrotic effect of metformin has been widely demonstrated. Fibrosis in the kidney after injury is associated with reduced expression of genes involved in both fatty acid and glycolytic energy metabolism. We have previously reported that the anti-fibrotic effect of metformin requires phospho...
Main Authors: | Geoff Harley, Marina Katerelos, Kurt Gleich, Mardiana Lee, Peter F. Mount, David A. Power |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9910667/?tool=EBI |
Similar Items
-
Mutation of regulatory phosphorylation sites in PFKFB2 does not affect the anti-fibrotic effect of metformin in the kidney.
by: Geoff Harley, et al.
Published: (2023-01-01) -
Suppression of PFKFB3-driven glycolysis restrains endothelial-to-mesenchymal transition and fibrotic response
by: Hao Zeng, et al.
Published: (2022-09-01) -
Phosphorylation of PFKFB4 by PIM2 promotes anaerobic glycolysis and cell proliferation in endometriosis
by: Chao Lu, et al.
Published: (2022-09-01) -
Myeloid PFKFB3-mediated glycolysis promotes kidney fibrosis
by: Qiuhua Yang, et al.
Published: (2023-11-01) -
Metformin and Glaucoma—Review of Anti-Fibrotic Processes and Bioenergetics
by: Daire J. Hurley, et al.
Published: (2021-08-01)